

# More Options for More Patients



For individuals living with advanced cancer, genomic profiling is an **important way to identify additional treatment options.**



Foundation Medicine has pioneered these efforts with **FoundationOne®**, our tissue-based comprehensive genomic profiling assay for solid tumors.

**But tissue biopsy is not the only path forward. We now have another option to help guide the way.**



With **FoundationACT™**, you can obtain comprehensive genomic results using only a **blood sample.**

## How It Works: Finding the Needle in a Haystack



**99%**  
sensitivity

**99%**  
specificity

Everyone's blood contains pieces of free-floating DNA, and in people with cancer, a fraction of that is circulating tumor DNA (ctDNA) that is shed from tumor cells.

**FoundationACT detects genomic alterations present in ctDNA** with best-in-class validated sensitivity.

FoundationACT is validated to probe **62 cancer-related genes across all 4 classes of genomic alterations.**<sup>1</sup>



Base pair substitutions



Insertions and deletions



Copy number variations



Rearrangements

## Making an Impact with Liquid Biopsy

FoundationACT has already demonstrated its ability to detect **potentially actionable mutations** in:



Lung cancer



Breast cancer



Gastrointestinal cancers



Prostate cancer

**This capability can have a profound clinical impact.**




Other ctDNA assay



FOUNDATIONACT

In one case, a NSCLC patient began responding to a specific targeted therapy after FoundationACT identified a **ROS1 fusion which had been missed by a different ctDNA assay.**<sup>2</sup>



In another case, FoundationOne detected a mutation that led to treatment on a targeted therapy.


Upon disease progression, another tissue sample could not be safely obtained.



FoundationACT liquid biopsy was used to confirm the presence of the original mutation and identified a **novel resistance mutation which helped to explain the disease progression.**<sup>3</sup>

## Providing a Complete View

Together with Foundation Medicine's **portfolio of assays and database of molecular insights**, FoundationACT can provide information about relevant targeted therapies or clinical trials that was **once unattainable to many patients.**



If you are treating someone with advanced cancer and need to change course, you now have

**More Options for More Patients**

1. Stephens, et al. Analytic validation of a clinical circulating tumor DNA assay for patients with solid tumors [abstract]. European Society for Medical Oncology. October 7-11, 2016. Copenhagen, Denmark.

2. Wang, et al. CD74-ROS1 Fusion in NSCLC Detected by Hybrid Capture-Based Tissue Genomic Profiling and ctDNA Assays. Journal of Thoracic Oncology. 2017;12(2):e19-e20.

3. Ou et al. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping. Journal of Thoracic Oncology. 2016;12(1):137-40.